Pharma Mar Valuation
| PHM Stock | EUR 75.50 0.10 0.13% |
At this time, the company appears to be undervalued. Pharma Mar SA holds a recent Real Value of €79.73 per share. The prevailing price of the company is €75.5. Our model determines the value of Pharma Mar SA from analyzing the company fundamentals such as Operating Margin of 0.33 %, return on equity of 0.47, and Shares Outstanding of 18.09 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Pharma Mar's price fluctuation is very steady at this time. Calculation of the real value of Pharma Mar SA is based on 3 months time horizon. Increasing Pharma Mar's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Pharma Mar is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharma Stock. However, Pharma Mar's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.5 | Real 79.73 | Hype 75.6 |
The real value of Pharma Stock, also known as its intrinsic value, is the underlying worth of Pharma Mar SA Company, which is reflected in its stock price. It is based on Pharma Mar's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pharma Mar's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pharma Mar SA helps investors to forecast how Pharma stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharma Mar more accurately as focusing exclusively on Pharma Mar's fundamentals will not take into account other important factors: Pharma Mar Total Value Analysis
Pharma Mar SA is at this time expected to have takeover price of 1.07 B with market capitalization of 1.09 B, debt of 33.39 M, and cash on hands of 42.72 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Pharma Mar fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.07 B | 1.09 B | 33.39 M | 42.72 M |
Pharma Mar Investor Information
About 27.0% of the company outstanding shares are owned by corporate insiders. The company last dividend was issued on the 13th of July 2022. Pharma Mar SA had 1:12 split on the 22nd of July 2020. Based on the analysis of Pharma Mar's profitability, liquidity, and operating efficiency, Pharma Mar SA is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Pharma Mar Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pharma Mar has an asset utilization ratio of 62.39 percent. This indicates that the Company is making €0.62 for each dollar of assets. An increasing asset utilization means that Pharma Mar SA is more efficient with each dollar of assets it utilizes for everyday operations.Pharma Mar Ownership Allocation
Pharma Mar owns a total of 18.09 Million outstanding shares. Pharma Mar has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pharma Mar Profitability Analysis
The company reported the revenue of 229.83 M. Net Income was 92.86 M with profit before overhead, payroll, taxes, and interest of 213.39 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Pharma Mar's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Pharma Mar and how it compares across the competition.
About Pharma Mar Valuation
The stock valuation mechanism determines Pharma Mar's current worth on a weekly basis. Our valuation model uses a comparative analysis of Pharma Mar. We calculate exposure to Pharma Mar's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pharma Mar's related companies.Pharma Mar, S.A., a biopharmaceutical company, engages in the discovery and development of marine-derived anticancer drugs in Spain and internationally. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain. PHARMA MAR operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 599 people.
8 Steps to conduct Pharma Mar's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Pharma Mar's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Pharma Mar's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Pharma Mar's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Pharma Mar's revenue streams: Identify Pharma Mar's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Pharma Mar's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Pharma Mar's growth potential: Evaluate Pharma Mar's management, business model, and growth potential.
- Determine Pharma Mar's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Pharma Mar's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Pharma Stock analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |